drugset / Trial / NCT01571232
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
Timeline
- Start
- 2012-04
- Primary completion
- 2014-02
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | Dexamethasone | Small molecule | 0.7 mg | Intravitreal |